Quick Answer
IGC Pharma, Inc. reported Stockholders Equity of $6.33 million for fiscal year 2025.
IGC Pharma, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $6.33M | -13.5% |
| 2024 | $7.32M | -50.9% |
| 2023 | $14.91M | -37.6% |
| 2022 | $23.89M | -27.2% |
| 2021 | $32.80M | +23.6% |
| 2020 | $26.54M | -21.0% |
| 2019 | $33.57M | +316.3% |
| 2018 | $8.06M | +9.6% |
| 2017 | $7.36M | -45.4% |
| 2016 | $13.48M | -5.3% |
| 2015 | $14.23M | +4.5% |
| 2014 | $13.63M | -5.6% |
| 2013 | $14.44M | -2.7% |
| 2012 | $14.84M | +122.6% |
| 2011 | $6.67M | -74.5% |
| 2010 | $26.15M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $8.09M | +9.7% | +33.1% |
| June 30, 2025 | $6.08M | -22.9% | -4.0% |
| March 31, 2025 | $6.33M | -13.5% | +1.1% |
| December 31, 2024 | $6.26M | -30.9% | -15.2% |
| September 30, 2024 | $7.38M | -47.7% | -6.4% |
| June 30, 2024 | $7.88M | -40.3% | +7.6% |
| March 31, 2024 | $7.32M | -50.9% | -19.1% |
| December 31, 2023 | $9.05M | -50.6% | -35.8% |
- IGC Pharma, Inc. showed a decrease of -13.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2010–2025 period, IGC Pharma, Inc.’s stockholders equity has declined by 75.8% (from $26.15 million to $6.33 million).
- The most recent figure is from IGC Pharma, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on June 27, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: